Visit our secure online portal to start your order.
AmbryPort LoginStill unsure about what option to choose? Learn more
Learn about our Re-requisitioning Policy
Click Here
Will insurance cover my patient's genetic test?
Click HereWhy partner with us?
Learn MoreWe are driven to give healthcare providers the most advanced testing information available so you can determine the best treatment options for your patients.
Test Code | 5504 |
Turnaround Time (TAT) | 14-21 days |
Number of Genes | 12 |
* On the same side of the family
PGLNext can detect >99.9% of described mutations in the included genes, when present (analytic sensitivity).
PGLNext analyzes 12 genes (listed above). All genes are evaluated by next generation sequencing (NGS) or Sanger sequencing of all coding domains, and well into the flanking 5’ and 3’ ends of all the introns and untranslated regions. Clinically significant intronic findings beyond 5 base pairs are always reported. Intronic variants of unknown or unlikely clinical significance are not reported beyond 5 base pairs from the splice junction. Additional Sanger sequencing is performed for any regions missing or with insufficient read depth coverage for reliable heterozygous variant detection. Reportable small insertions and deletions, potentially homozygous variants, variants in regions complicated by pseudogene interference, and single nucleotide variant calls not satisfying 100x depth of coverage and 40% het ratio thresholds are verified by Sanger sequencing.1 Gross deletion/duplication analysis is performed for the covered exons and untranslated regions of all 12 genes using read-depth from NGS data with confirmatory multiplex ligation-dependent probe amplification (MLPA) and/or targeted chromosomal microarray.
1. Mu W, et al. Sanger confirmation is required to achieve optimal sensitivity and specificity in next-generation sequencing panel testing. J Mol Diagn. 2016. 18(6):923-932.
HGVS | HUGO Gene Name | Disease |
m.583G>A | MT-TF | MELAS / MM & EXIT |
m.1494C>T | MT-RNR1 | DEAF |
m.1555A>G | MT-RNR1 | DEAF |
m.1606G>A | MT-TV | AMDF |
m.1644G>A | MT-TV | HCM+MELAS |
m.3243A>G | MT-TL1 | MELAS / LS/DMDF / MIDD / SNHL / FSGS / CPEO |
m.3251A>G | MT-TL1 | MELAS |
m.3252A>G | MT-TL1 | MELAS |
m.3256C>T | MT-TL1 | MELAS |
m.3260A>G | MT-TL1 | MMC |
m.3271T>C | MT-TL1 | MELAS |
m.3291T>C | MT-TL1 | MELAS / Myopathy / Deafness+Cognitive Impairment |
m.3302A>G | MT-TL1 | MM |
m.3303C>T | MT-TL1 | MMC |
m.3460G>A | MT-ND1 | LHON |
m.3635G>A | MT-ND1 | LHON |
m.3697G>A | MT-ND1 | MELAS/LS/LDYT |
m.3700G>A | MT-ND1 | LHON |
m.3733G>A | MT-ND1 | LHON |
m.3890G>A | MT-ND1 | Progressive encephalomyopathy / LS / optic atrophy |
m.4171C>A | MT-ND1 | LHON |
m.4269A>G | MT-TI | FICP |
m.4274T>C | MT-TI | CPEO/Motor Neuron Disease |
m.4298G>A | MT-TI | CPEO / MS |
m.4300A>G | MT-TI | MICM |
m.4308G>A | MT-TI | CPEO |
m.4332G>A | MT-TQ | Encephalopathy / MELAS |
m.5537_5538insT | MT-TW | Leigh Syndrome |
m.5650G>A | MT-TA | Myopathy |
m.5703G>A | MT-TN | CPEO/MM |
m.7222A>G | MT-CO1 | peripheral neuropathy, muscle weakness, ptosis, abnormal muscle pathology |
m.7445A>G | MT-TS1 | SNHL |
m.7471dupC | MT-TS1 | PEM/AMDF/Motor neuron disease-like |
m.7497G>A | MT-TS1 | MM / EXIT |
m.7511T>C | MT-TS1 | SNHL |
m.8344A>G | MT-TK | MERRF |
m.8356T>C | MT-TK | MERRF |
m.8363G>A | MT-TK | MICM+DEAF/ MERRF/ Autism/ LS/ Ataxia+Lipomas |
m.8969G>A | MT-ATP6 | Mitochondrial Myopathy, Lactic Acidosis, |
m.8993T>C | MT-ATP6 | NARP/Leigh Disease/MILS/other |
m.8993T>G | MT-ATP6 | NARP/Leigh Disease/MILS/other |
m.9176T>C | MT-ATP6 | FBSN/Leigh Disease |
m.9176T>G | MT-ATP6 | Leigh Disease/Spastic Paraplegia |
m.9185T>C | MT-ATP6 | Leigh Disease/Ataxia/NARP-like disease |
m.10010T>C | MT-TG | PEM |
m.10158T>C | MT-ND3 | Leigh Disease |
m.10191 T>C | MT-ND3 | Leigh Disease/Leigh-like Disease/ESOC |
m.10197G>A | MT-ND3 | Leigh Disease/Dystonia/Stroke/LDYT |
m.10663T>C | MT-ND4L | LHON |
m.11777C>A | MT-ND4 | Leigh Disease |
m.11778G>A | MT-ND4 | LHON, Progressive Dystonia |
m.12147G>A | MT-TH | MERRF-MELAS/Enchephalopathy |
m.12258C>A | MT-TS2 | DMDF / RP+SNHL |
m.12315G>A | MT-TL2 | CPEO/KSS |
m.12320A>G | MT-TL2 | Myopatrhy |
m.12706T>C | MT-ND5 | Leigh Disease |
m.13513G>A | MT-ND5 | Leigh Disease/MELAS/LHON-MELAS Overlap Syndrome |
m.13514A>G | MT-ND5 | Leigh Disease/MELAS |
m.14459G>A | MT-ND6 | LDYT/Leigh Disease |
m.14482C>G | MT-ND6 | LHON |
m.14484T>C | MT-ND6 | LHON |
m.14487T>C | MT-ND6 | Dystonia/Leigh Disease/Ataxia |
m.14495A>G | MT-ND6 | LHON |
m.14568C<T | MT-ND6 | LHON |
m.14674T>C | MT-TE | Reversible COX deficiency myopathy |
m.14709T>C | MT-TE | MM+DMDF / Encephalomyopathy |
m.14849T>C | MT-CYB | EXIT / Septo-Optic Dysplasia |
m.15579A>G | MT-CYB | Multisystem Disorder, EXIT |